Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 combinations in advanced colorectal cancer
NCT07358585Phase 2Not yet recruiting
- Sponsor
- Henlius
- Start
- Jan 2026
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in colorectal cancer (CRC), sponsored by Henlius. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
HLX43
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07358585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358585.